» Articles » PMID: 31993196

Work Up of Fatty Liver by Primary Care Physicians, Review

Overview
Publisher Wolters Kluwer
Specialty Medical Education
Date 2020 Jan 30
PMID 31993196
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is an overarching term that refers to abnormal deposition of lipids in the liver and is used to describe the spectrum of disease ranging from hepatic steatosis to nonalcoholic steatohepatitis to cirrhosis. NAFLD is the most common cause of chronic liver disease and the second most common cause of cirrhosis. Although the pathophysiology is not completely understood, there is a strong link between NAFLD and metabolic syndrome. This review focuses on the workup of NAFLD in the primary care setting, from differential diagnoses to assessing fibrosis via predictive models that use commonly used laboratory values, biomarkers, and imaging. The purpose of this review article is to provide a set of screening and diagnostic tools for all primary care physicians in order to better manage patients with NAFLD.

Citing Articles

Fatty Liver Disease in Patients with Prediabetes and Overweight or Obesity.

Arias-Fernandez M, Fresneda S, Abbate M, Torres-Carballo M, Huguet-Torres A, Sanchez-Rodriguez C Metabolites. 2023; 13(4).

PMID: 37110189 PMC: 10146012. DOI: 10.3390/metabo13040531.


To scan or not to scan: Use of transient elastography in an integrated health system.

Stein L, Mittal R, Song H, Chung J, Sahota A World J Hepatol. 2023; 15(3):419-430.

PMID: 37034236 PMC: 10075005. DOI: 10.4254/wjh.v15.i3.419.


Relation of Dietary Patterns and Nutritional Profile to Hepatic Fibrosis in a Sample of Lebanese Non-Alcoholic Fatty Liver Disease Patients.

Sayegh N, Heraoui G, Younes H, Sayegh L, Boulos C, Sayegh R Nutrients. 2022; 14(12).

PMID: 35745284 PMC: 9229197. DOI: 10.3390/nu14122554.

References
1.
Huang Y, Adams L, Joseph J, Bulsara M, Jeffrey G . The ability of Hepascore to predict liver fibrosis in chronic liver disease: a meta-analysis. Liver Int. 2016; 37(1):121-131. DOI: 10.1111/liv.13116. View

2.
Kaur J . A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014; 2014:943162. PMC: 3966331. DOI: 10.1155/2014/943162. View

3.
Sanyal A, Chalasani N, Kowdley K, McCullough A, Diehl A, Bass N . Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362(18):1675-85. PMC: 2928471. DOI: 10.1056/NEJMoa0907929. View

4.
Dulai P, Sirlin C, Loomba R . MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol. 2016; 65(5):1006-1016. PMC: 5124376. DOI: 10.1016/j.jhep.2016.06.005. View

5.
Hajifathalian K, Sagvand B, McCullough A . Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. Hepatology. 2018; 70(2):511-521. PMC: 6380949. DOI: 10.1002/hep.30226. View